NextEra Energy recorded a big jump in profit for the second quarter from climbing revenue and a decline in costs. The clean-energy company posted a profit of $3.14 billion, or $1.50 a share, up from ...
Shares of Outlook Therapeutics posted wide swings as the Food and Drug Administration approved the company's Lytenava for treatment of neovascular age-related macular degeneration.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results